Compare KLA Corp. (KLAC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Revvity Inc — how do they compare? KLA Corp. trades at $209.04 (market cap $261.92B), while Revvity Inc trades at $116.1 (market cap $12.91B). The key difference: KLA Corp. is far larger — about 20.3× Revvity Inc's market cap, and KLA Corp. pays the higher dividend (0.46%). Which is the better fit depends on your goals.
| KLAC | RVTY | |
|---|---|---|
Market Cap | $261.92B | $12.91B |
Sector | Technology | Technology |
52-Week High | $301.71 | $117.75 |
52-Week Low | $84.39 | $82.26 |
Enterprise Value | $263.17B | $15.23B |
Dividend Yield | 0.46% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $209.16, up 8.52% over 24 hours, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a 35.57% net income margin and 87.5% ROE, supported by a recent dividend hike and stock split. Analyst consensus is bullish with a $246.93 price target, though elevated valuation ratios like a P/E of 54.77 warrant caution.
Outlook remains positive driven by AI-driven semiconductor equipment demand, but risks include high valuation sensitivity and cyclical industry exposure. The stock offers growth potential with disciplined risk management advised given overbought technical conditions and macroeconomic uncertainties.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
